Shopping Cart
Remove All
Your shopping cart is currently empty
Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $118 | - | In Stock | |
| 5 mg | $328 | - | In Stock | |
| 10 mg | $529 | - | In Stock | |
| 25 mg | $843 | - | In Stock | |
| 50 mg | $1,130 | - | In Stock |
| Description | Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer. |
| In vitro | Cixutumumab showed significant growth inhibition of at least 50% in CHLA-9, TC-71 and Rh41 cell lines after 96 hours of treatment at concentrations ranging from 0.01 to 100 nM. [1] |
| In vivo | In an in vivo model of the Pediatric Preclinical Testing Program (PPTP), Cixutumumab, given to rats by intraperitoneal injection at a dose of 1 mg twice weekly for six weeks, showed potent antitumor effects and significantly inhibited the progression of solid tumors. [1] |
| Synonyms | NSC742460, NSC 742460, LY3012217, LY 3012217, IMC-A12, IMCA12 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IGF1-R/IGFR1/CD221 |
| Molecular Weight | 146.32 kDa |
| Cas No. | 947687-12-9 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.